A Phase II Trial of Mitomycin in Patients with Epithelial Ovarian Carcinoma Resistant to Cisplatin or Carboplatin
- 1 October 1990
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 13 (5) , 416-419
- https://doi.org/10.1097/00000421-199010000-00010
Abstract
Intravenous bolus mitomycin was given at a dose of 10–12 mg/m2 to patients with epithelial ovarian cancer resistant to cisplatin or carboplatin. There were three (12%) partial responses and no complete responses in the 25 patients so treated.Keywords
This publication has 5 references indexed in Scilit:
- Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.Journal of Clinical Oncology, 1987
- Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.Journal of Clinical Oncology, 1985
- Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumorsThe American Journal of Medicine, 1985
- PHASE-II STUDY OF LOW-DOSE MITOMYCIN IN PATIENTS WITH OVARIAN-CANCER PREVIOUSLY TREATED WITH CHEMOTHERAPY1985
- Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdensCancer, 1983